Pediatrics in Review Note to Institutions for Site Subscriptions
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mezoff, A. G
Right arrow Articles by Balistreri, W. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mezoff, A. G
Right arrow Articles by Balistreri, W. F

Peptic Ulcer Disease in Children

Adam G Mezoff MD1
William F Balistreri MD2
1 Assistant Professor of Pediatrics and Medicine, Wright State University School of Medicine, Director, Gastroenterology & Nutrition, Children's Medical Center, Dayton, OH.
2 Professor of Pediatrics and Director, Gastroenterology & Nutrition, Children's Hospital Medical Center, Cincinnati, OH.

The term peptic ulcer disease describes a group of disorders, rather than a single pathologic process. It is recognized increasingly in children, often with long-term ramifications. In the past decade, management of patients who have peptic ulcer disease has changed dramatically. Antacid therapy has given way to treatment with histamine (H2) receptor antagonists, a new class of pharmacologic agents that has fostered a billion dollar industry. Other modalities of treatment have been developed as well, such as cytoprotective agents (sucralfate) and proton pump inhibitors (omeprazole), which are based on research into the pathophysiology of gastric acid disorders. In addition, the discovery of an infectious agent (Helicobacter pylori) that contributes to the formation of peptic ulcers has led to a reevaluation of the traditional approach to diagnosis and treatment of abdominal pain in children.

Duodenal ulcers are defined as mucosal defects penetrating the mucosa, submucosa, and muscularis mucosa of the duodenum. Gastric ulcers are defined as mucosal defects that penetrate the muscularis mucosa of the stomach. Primary ulcers are those that have no known underlying cause. Secondary ulcers are associated with a known ulcerogenic event such as stress, burns, or ingestion of nonsteroidal anti-inflammatory medications. A discussion of peptic inflammation that typically does not cause ulceration, such as esophagitis, is beyond the scope of this review.




This article has been cited by other articles:


Home page
J Clin PharmacolHome page
S. M. Abdel-Rahman, F. K. Johnson, G. Gauthier-Dubois, I. E. Weston, and G. L. Kearns
The Bioequivalence of Nizatidine (Axid(R)) in Two Extemporaneously and One Commercially Prepared Oral Liquid Formulations Compared with Capsule
J. Clin. Pharmacol., February 1, 2003; 43(2): 148 - 153.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics  Pediatrics in Review
Copyright © 1995 by the American Academy of Pediatrics.